Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes | Aplastic Anemia & MDS International Foundation Return to top.

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes

Journal Title: 
Best Pract Res Clin Haematol
Primary Author: 
Itzykson R
Itzykson R, Kosmider O, Fenaux P
Original Publication Date: 
Tuesday, December 31, 2013

During many years, very limited data had been available on specific gene mutations in MDS in particular due to the fact that balanced chromosomal translocations (which have allowed to discover many "leukemia" genes) are very rare in MDS, while chromosomal deletions are generally very large, making it difficult to identify genes of interest. Recently, the advent of next generation sequencing (NGS) techniques has helped identify somatic gene mutations in 75-80% of MDS, that cluster mainly in four functional groups, i.e. cytokine signaling (RAS genes), DNA methylation, (TET2, IDH1/2, DNMT3a genes) histone modifications (ASXL1 and EZH2 genes), and spliceosome (SF3B1 and SRSF2 genes) along with mutations of RUNX1 and TP 53 genes. Most of those mutations, except SF3B1 and TET2 mutations, are associated with an overall poorer prognosis, while some gene mutations (mainly TET2 mutation), may be associated to better response to hypomethylating agents. The frequent mutations of epigenetic modulators in MDS appear to largely contribute to the importance of epigenetic deregulation (in particular gene hypermethylation and histone deacetylation) in MDS progression, and may account at least partially for the efficacy of hypomethylating agents in the treatment of MDS.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with